NASDAQ$PIII

P3 Health Partners Inc · Q1 2026 earnings

Q1 2026 earnings · · Investor relations

Briefing

P3 Health Partners Inc reported total operating revenue of $386.4 million and net income of $3.0 million for the first quarter ended March 31, 2026.

P3 Health Partners Inc turned to positive net income in Q1 2026 after prior period losses, driven by higher per-member rates and significantly lower medical expenses despite reduced membership. The company achieved strong medical margin expansion and positive Adjusted EBITDA. Operations remain focused on one reportable segment with capitated revenue comprising the vast majority of total revenue.

  • Total operating revenue grew 4% year-over-year to $386.4 million, primarily from improved capitated rates offsetting lower at-risk membership.
  • Net income reached $3.0 million compared to a $44.2 million loss in the prior-year quarter, aided by a $36.0 million reduction in medical expense.
  • Medical margin expanded sharply to $73.7 million from $17.2 million, reflecting favorable claims development and cost management.
  • Adjusted EBITDA turned positive at $25.8 million versus a $22.2 million loss, while the company maintained compliance with debt covenants.

Headline financials

Total Revenue

$386M

Previous: $373M+3.5%
EPS (adj)

$0.37

Previous: -$6.28+105.9%
Medical Margin

$73.7M

Previous: $17.2M+328.2%
Net Income

$1.22M

Previous: -$20.5M+106.0%
Operating Income

$8.24M

Previous: -$38.1M+121.6%
Cash & Equivalents

$25.5M

No prior period
Total Assets

$674M

No prior period

Revenue & EPS history

P3 Health · Revenue · Quarterly

$386M

Q1 2026+3.5%vs Q1 2025
Beat estimate in 9 of 13 quarters(69%)
ActualEstimate

Revenue by segment

P3 Health · $386M total across 2 segments · Q1 2026

  • Capitated Revenue
    $379M
  • Other Revenue
    $6.89M

Forward guidance

Management continues to prioritize membership quality, cost discipline, and capital structure optimization amid ongoing liquidity considerations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

-3.8%

Avg return

Earnings day

+2.0%

Avg return

5 days after

-15.6%

Avg return

30 days after

37%

7 / 19 earnings

Positive

+11.2%

Q1 2026

Best reaction

-36.8%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+11.2%+194.4%
Q4 2026+0.7%-1.8%-5.4%
Q3 2025+0.4%-12.6%-25.9%
Q2 2025-2.5%+5.4%+23.9%
Q1 2025-0.6%-5.9%-19.5%
Q4 2024-4.5%+1.1%-1.2%
Q3 2024-36.8%-42.2%-46.0%
Q2 2024-2.5%-8.7%-24.1%
Q1 2024+2.6%-11.8%-21.6%
Q4 2023-13.3%-22.4%-56.3%
Q4 2021+3.1%-7.6%-12.2%
Q3 2023-2.1%-8.8%-19.0%
Q2 2023+0.9%-10.8%-5.0%
Q4 2022-5.9%-12.7%+15.5%
Q3 2022-11.8%-19.7%-33.5%
Q1 2022-5.9%+2.1%-16.8%
Q2 2022-4.1%+0.6%-14.0%
Q3 2021+0.1%+0.3%-19.9%
Q2 2021-0.7%-0.2%+0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro